CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2009 | — | Replaced |
| 1st Quarter - Amendment (this page) | Jul 20, 2009 | $200,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Medicare/Medicaid MMM
Address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Budget/Appropriations BUD
Labor, Health and Human Services, and Education, and Related Agencies Appropriations for FY10, provisions on NIH and biodefense/pandemic funding, and math and science education program funding. Commerce, Justice, Science Appropriations for FY10, provisions on funding for NSF and for Professional Science Masters program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Education EDU
Support funding for Professional Science Masters program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Medical/Disease Research/Clinical Labs MED
Labor, Health and Human Services, and Education, and Related Agencies Appropriations for FY10, provisions on NIH and biodefense/pandemic funding. Support removal of embryonic stem cell funding restrictions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Health Issues HCR
Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.